[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  S A I ™️ [@WallStSai](/creator/twitter/WallStSai) on x 7068 followers Created: 2025-07-12 21:04:58 UTC $XBI $MDGL $AKRO $ETNB $VKTX New Study Projects Alarming Rise in MASLD Related Deaths by 2040 A recent U.S. study just published in JAMA Network Open has projected that deaths from Metabolic dysfunction–Associated Steatotic Liver Disease (MASLD) will nearly double by 2040, climbing from XXXX to XXXX per XXXXXXX persons. This follows a troubling rise in MASLD-related mortality between 2006 and 2023, with the sharpest increases seen in: •Adults 65+ (projected rate more than doubling from XXXX to 7.12) •Hispanic and non-Hispanic White populations •Nonmetropolitan/rural areas Despite increased awareness and emerging treatments, MASLD remains severely underdiagnosed, especially in high-risk populations. These projections are a wake-up call for clinicians, researchers, and policymakers: without expanded screening, early intervention, and equitable care, we risk an avoidable surge in liver-related deaths. This is personal, because for every patient at risk of #MASH progression, these numbers are not just statistics. They are Lives! Right now there is only one FDA Approved drug ‘Rezdiffra’ to treat #MASH Source: JAMA Network Open  XXXXX engagements  **Related Topics** [$etnb](/topic/$etnb) [$akro](/topic/$akro) [$xbi](/topic/$xbi) [$mdgl](/topic/$mdgl) [$vktx](/topic/$vktx) [Post Link](https://x.com/WallStSai/status/1944140953398259974)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
S A I ™️ @WallStSai on x 7068 followers
Created: 2025-07-12 21:04:58 UTC
$XBI $MDGL $AKRO $ETNB $VKTX
New Study Projects Alarming Rise in MASLD Related Deaths by 2040
A recent U.S. study just published in JAMA Network Open has projected that deaths from Metabolic dysfunction–Associated Steatotic Liver Disease (MASLD) will nearly double by 2040, climbing from XXXX to XXXX per XXXXXXX persons. This follows a troubling rise in MASLD-related mortality between 2006 and 2023, with the sharpest increases seen in: •Adults 65+ (projected rate more than doubling from XXXX to 7.12) •Hispanic and non-Hispanic White populations •Nonmetropolitan/rural areas
Despite increased awareness and emerging treatments, MASLD remains severely underdiagnosed, especially in high-risk populations. These projections are a wake-up call for clinicians, researchers, and policymakers: without expanded screening, early intervention, and equitable care, we risk an avoidable surge in liver-related deaths.
This is personal, because for every patient at risk of #MASH progression, these numbers are not just statistics. They are Lives! Right now there is only one FDA Approved drug ‘Rezdiffra’ to treat #MASH
Source: JAMA Network Open
XXXXX engagements
